| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | Vinorelbine | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | 0.0084 | 1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0023 | 1 |